MiNK Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Mink Therapeutics reported a first-quarter 2026 net loss of approximately $2.7 million, or $0.57 per share, compared with approximately $2.8 million, or $0.70 per share, in the same period in 2025.
- The company ended 2025 with approximately $13.4 million in cash and cash equivalents, repaid approximately $5.2 million associated with the Agenus convertible note during the first quarter of 2026, raised approximately $3 million through its at-the-market sales agreement in the 3 months ended March 31st, 2026, and ended the quarter with approximately $9.5 million in cash.
- Mink announced initiation of a randomized Phase 2 trial of AGENT-797 plus standard of care versus placebo plus standard of care in patients with severe acute lung injury and respiratory distress identified using globally recognized ARDS criteria.
- At AACR, investigators presented Phase 2 data in heavily pretreated, checkpoint-refractory gastroesophageal cancer; median overall survival extended beyond 23 months in the immune-primed cohort, and several patients remained alive years after dosing.
- Mink reported that translational analyses showed different immune outputs from the same donor-derived product in cancer and ARDS: Th1-oriented tumor-killing activity in cancer and restoration-associated immune signaling in severe lung injury.
- The company announced a first-quarter collaboration with See Further to advance its PRAME-targeted TCR-engineered INKT cell therapy for pediatric cancers, with non-dilutive support for IND-enabling activities and potential downstream commercial participation.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
The conference over to Stefanie Perna-Nacar from MiNK Investor Relations. Stephanie, please go ahead. Thank you, operator.
Thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including those related to our clinical development, regulatory and commercial plans, timelines for data releases, and partnership opportunities. These statements are subject to risks and uncertainties. Please refer to our SEC filings, also available on our website, for a detailed description of these risks. Joining me today are Dr. Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics, Dr. Terese Hammond, Head of Development, and Melissa Orilall, Principal Financial Officer. I'd like to turn the call over to Dr. Buell to highlight our progress from this quarter.
Jennifer? Thank you, Stephanie. Good morning, everyone, and thank you for joining us today.
Over the past several weeks, we've presented data at four major international scientific meetings, beginning with findings in pulmonary fibrosis at the Keystone Symposia in February, followed by a presentation of our phase II clinical data in refractory gastric cancer at AACR in April. Most recently, in fact, just earlier this week, we presented mechanistic findings at the American Society of Gene & Cell Therapy, showing the context-dependent immune activity of invariant natural killer T cells in cancer and severe lung injury. We're also very excited that next week, Dr. Terese Hammond, our head of pulmonary inflammatory diseases, will present at the American Thoracic Society Conference, the International Conference, in Orlando, Florida.
She'll describe a combination of our invariant natural killer T cell technology, agenT-797, in combination with an IL-15 super agonist named ANKTIVA, and the modulation of dysregulated inflammation and pathogen-clearing responses in severe pulmonary fungal infection. Taken together, these presentations describe an increasingly coherent biologic and clinical story around iNKTs in cancer, severe lung injury, fibrosis, and immune dysfunction overall. For those newer to MiNK, our focus is on the development of off-the-shelf iNKT cell therapies designed to repair dysregulated immune biology in diseases characterized by immune failure, inflammatory injury, and impaired pathogen control. Unlike conventional cell therapy, 797 is administered without lymphodepletion or HLA matching. In the approximately 100 treated patients to date, we've observed a favorable safety profile together with increasingly reproducible biologic and clinical observations. What continues to distinguish this platform is its clinical activity and its practicality.
At MiNK, we believe we've addressed many of the barriers that have historically limited the broader application of cell therapy. These include manufacturing complexity, scalability, timing, and deployability in acute care settings. As a result, we are now able to evaluate our living medicines in diseases and clinical environments that were previously impractical for cell therapy due to operational complexity and cost. That same practicality is central to how we're expanding our platform through selective partnerships. In the first quarter of this year, we announced a collaboration with C-Further to advance our PRAME-targeted TCR-engineered iNKT cell therapy for pediatric cancers. This program's important not only because it brings non-dilutive support and potential meaningful commercial economics, but also because it applies our off-the-shelf iNKT platform to a setting where speed, tolerability, and access matter profoundly.
For children with aggressive cancers, delays from individualized manufacturing and intensive pretreatment can be especially challenging. The C-Further collaboration allows us to extend MiNK's platform into a validated tumor antigen strategy while preserving our focus and capital discipline. I'll summarize our recent core data presentation before turning it over to Dr. Hammond. At AACR in April, investigators from Memorial Sloan Kettering presented data from our phase II study in gastroesophageal cancer. This trial is an investigator-sponsored trial led by the Division Chief, Dr. Yelena Janjigian, and her colleague, Dr. Sam Cytryn. The population was heavily pretreated, checkpoint refractory, with historically poor expected outcomes and limited therapeutic options after failure on prior first-line therapy. We observed prolonged survival in patients who received induction immune therapy prior to chemotherapy, including emergence of a meaningful tail of the survival curve. These were patients whose expected survival is measured typically in months.
Yet here, median overall survival extended beyond 23 months in the immune-primed cohort, and several patients remain alive years after dosing. In refractory gastric cancer, that is highly unusual. What's become increasingly important to us over time is not simply whether transient responses occur, but whether coordinated modulation of dysfunctional immune biology can actually fundamentally alter long-term disease trajectory and survival in patients with otherwise limited therapeutic options. As follow-up continues to mature, and this includes follow-up from our phase I trial, we observe durability of survival in multiple tumor types, and that includes gastric cancer, thymoma, renal cell carcinoma, and germ cell cancers. Importantly, these observations were accompanied by translational findings that show coordinated modulation of the tumor microenvironment, including activation of important tumor-killing immune pathways, restoration of exhausted immune responses, and remodeling of suppressive myeloid biology.
Increasingly, these intrinsic immune-modulating properties appear to connect directly with the biology that we are now observing in inflammatory lung injury and ARDS. At the American Society of Gene & Cell Therapy Conference this week in Boston, Dr. Yan Sun from our team presented translational analyses from patients with cancer and ARDS treated with the same donor-derived 797 product. Very important. We observed distinct immune outputs depending on the disease environment. This supports our belief that iNKT cells participate in modulating immune biology across profoundly different disease states. Again, the same donor-derived product manufactured through our GMP process produced profoundly different immune biology in very different disease settings. In cancer, the biology showed a Th1-oriented tumor-killing cytotoxic immune activation, while in severe lung injury, the profile shifted towards restoration-associated immune signaling, and Dr. Hammond will go into this in more detail.
Importantly, these observations emerged again from the same unmodified allogeneic product. Yesterday, we announced the initiation of our randomized phase II clinical trial evaluating 797 in combination with standard of care versus placebo plus standard of care in patients with severe acute lung injury and respiratory distress identified using globally recognized ARDS criteria. This study has been carefully designed with endpoints and operational infrastructure that we believe will not only validate the observations in our earlier phase I/II study, and if prospectively confirmed, support rapid development through a seamless phase II/III pathway integrated already into the protocol's framework. This structure allows us to move very efficiently from validation of our earlier observations into a potential registrational development strategy without interruption between phases of development. We expect to speak with the FDA in the impending weeks on our trial design and development plans. The need for new medications is significant.
Acute lung injury and ARDS remain among the most serious unresolved conditions in critical care. ARDS affects an estimated 3 million people globally and approximately 200,000 people annually in the U.S., accounting for about 25% of mechanically ventilated ICU patients. Mortality remains very high. Approximately 40%-50% of patients die from their disease. Despite decades of research, development of medicines for patients with this critical pulmonary problem, or ARDS, has been challenged by biologic heterogeneity and the complexity of prolonged illness. Prior approaches, including mesenchymal stromal cell, or MSC therapies, demonstrated feasibility and a favorable safety profile, but failed to consistently improve survival in randomized studies. In part, because broad immunosuppressive or paracrine approaches may be insufficient in patients who simultaneously require modulation of an injurious inflammation together with preservation of pathogen-clearing immune function.
We believe, based on our observations, that iNKT cells, and specifically agenT-797, may represent a fundamentally different biologic approach. Unlike MSCs, iNKTs are active immune effector cells capable of localized modulation of inflammatory signaling together with coordinated activation of innate and adaptive immune pathways, including the ability to clear systemic pathogens. Our intended target population are patients who can be identified clearly, characterized biologically, and stratified thoughtfully using globally recognized clinical and physiologic criteria. That matters from both a regulatory perspective as well as a clinical perspective. Critically, this patient population is a population where we believe we have already observed meaningful biologic and clinical signals, both in our clinical trials and through continued emergency use experience in critically ill patients who have few remaining therapeutic options.
Our findings have emerged in real-world ICU environments, and specifically Dr. Hammond is operating in those environments daily, and she was the lead investigator on our trial. Through the data that we have now published and what we expect to see in the future is that we have observed evidence of local immune modulation within the lung, together with reductions in harmful inflammatory signaling and reduction in secondary infections. Dr. Hammond will speak more about this shortly. I want to highlight an important component of this effort. It is part of a partnership that we have developed with First Lviv Territorial Medical Union and UNBROKEN Ukraine. Our study has been approved by the Ukrainian Ministry of Health and now cleared the U.S. FDA for dosing. Our team has had the opportunity to spend time on site evaluating the hospital, talking with the team, meeting with the critical care team, discussing their capabilities.
We also reviewed the translational infrastructure and most importantly, the patients. What we observed was remarkable. The clinical sophistication and quality of care being delivered under unimaginably difficult wartime conditions was incredible. We believe this collaboration creates an opportunity to evaluate iNKT-based cell therapies in patients where the biology is particularly relevant and increasingly common in modern warfare and critical care medicine. Modern conflict is increasingly producing survivors after devastating injury, but survival is accompanied by complications including multidrug-resistant pathogens, chronic inflammatory issues, and downstream fibrosis. Programs such as BARDA-funded BREATHE program have demonstrated that appropriately targeted anti-inflammatory interventions can improve survival in patients with severe respiratory compromise.
We believe the next evolution are therapies capable of not only of dampening harmful inflammation, as we've observed with 797, but also restoring immune coordination and pathogen control in patients with critical illness and immune exhaustion. Changing the trajectory of disease in these populations is becoming increasingly important, not only to clinicians, but also to governments and global health systems. Our program also demonstrates the practicality of an off-the-shelf approach in a real-world critical care setting, these environments where complex individualized manufacturing are simply not feasible. The ability to deliver cryopreserved allogeneic therapy rapidly without lymphodepletion or HLA matching is operationally important. As I mentioned, the trial is now cleared to proceed by the Ministry of Health in Ukraine, as well as by the U.S. FDA. We're proud to support this initiative alongside physicians and humanitarian leaders, and we're grateful to contribute to this important effort at a time when it's so urgently needed.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
